MarketCap
Facebook
X
Telegram
AbbVie EBITDA | ABBV
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.8 B | 9.9 B | 13.5 B | 18.9 B | 18.7 B | 12 B | 15 B | 8.15 B | 11.1 B | 10.6 B | 8.37 B | 4.2 B | 6.56 B | 6.97 B | 5.57 B | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.9 B | 4.2 B | 11 B |
Quarterly EBITDA AbbVie
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.63 B | 4.18 B | 2.1 B | 5.08 B | 3.91 B | 4.02 B | 4.18 B | 2.98 B | 2.48 B | 4.7 B | 2.95 B | - | 4.78 B | 3.5 B | 4.92 B | - | 4.53 B | 4.64 B | 4.31 B | - | 3.43 B | 901 M | 3.72 B | - | 2.73 B | 3.51 B | 3.13 B | - | 3.27 B | 2.88 B | 3.02 B | - | 2.8 B | 2.77 B | 2.51 B | - | 2.46 B | 2.5 B | 2.38 B | - | 1.99 B | 1.96 B | 1.78 B | - | 1.05 B | 1.62 B | 1.44 B | - | 1.47 B | 1.55 B | 1.4 B | - | 1.69 B | 1.54 B | 1.12 B | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.63 B | 901 M | 2.97 B |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
-22.6 M | - | - | - |  Russia |
 |
AbCellera Biologics
ABCL
|
-199 M | $ 10.89 | 4.11 % | $ 3.25 B |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-106 M | - | -14.46 % | $ 27.9 M |  USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-43.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-57.9 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
-86.9 M | $ 5.42 | 0.18 % | $ 287 M | USA |
 |
iTeos Therapeutics
ITOS
|
-158 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
83 K | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-50.2 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
-115 M | - | - | $ 28.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-3.21 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
-48.3 M | $ 2.0 | 0.3 % | $ 726 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-9.76 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.7 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-37.8 M | $ 5.12 | 0.1 % | $ 981 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |
 |
NextCure
NXTC
|
-55.4 M | $ 7.0 | 0.55 % | $ 19.9 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-29.5 M | - | 17.91 % | $ 11.1 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-10.8 M | $ 37.01 | 0.27 % | $ 1.77 T |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
106 M | $ 27.83 | 0.32 % | $ 4.69 B | USA |
 |
Axcella Health
AXLA
|
-76.6 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-79.2 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-89 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
228 K | $ 7.06 | 0.41 % | $ 308 M | USA |
 |
Baudax Bio
BXRX
|
-17.9 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
-41.8 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
-101 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
-64.2 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
-127 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
-7.57 M | - | - | $ 789 M | USA |
 |
AC Immune SA
ACIU
|
-69.3 M | $ 2.76 | 2.6 % | $ 278 M |  Schweiz |
|
Cerevel Therapeutics Holdings
CERE
|
-442 M | - | - | $ 7.29 B | USA |
 |
Aclaris Therapeutics
ACRS
|
-75.9 M | $ 5.32 | 1.27 % | $ 652 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Adagene
ADAG
|
-21 M | $ 3.4 | 2.72 % | $ 201 M |  China |
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.07 | 0.45 % | $ 136 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
-7.8 M | $ 4.9 | 0.08 % | $ 3.28 M | USA |
 |
ADMA Biologics
ADMA
|
199 M | $ 9.23 | 0.16 % | $ 2.2 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-41.1 M | $ 24.2 | 0.08 % | $ 3.67 B | USA |
 |
Agenus
AGEN
|
-10.2 M | $ 6.94 | 0.73 % | $ 206 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-467 M | $ 33.6 | 0.16 % | $ 1.95 B | USA |